Logo image of GTBP

GT BIOPHARMA INC (GTBP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GTBP - US36254L3087 - Common Stock

0.64 USD
-0.01 (-1.45%)
Last: 12/9/2025, 8:04:29 PM
0.64 USD
0 (0%)
After Hours: 12/9/2025, 8:04:29 PM
Fundamental Rating

0

GTBP gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. GTBP has a bad profitability rating. Also its financial health evaluation is rather negative. GTBP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GTBP had negative earnings in the past year.
GTBP had a negative operating cash flow in the past year.
GTBP had negative earnings in each of the past 5 years.
In the past 5 years GTBP always reported negative operating cash flow.
GTBP Yearly Net Income VS EBIT VS OCF VS FCFGTBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of GTBP (-439.13%) is worse than 96.05% of its industry peers.
Industry RankSector Rank
ROA -439.13%
ROE N/A
ROIC N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTBP Yearly ROA, ROE, ROICGTBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GTBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTBP Yearly Profit, Operating, Gross MarginsGTBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, GTBP has more shares outstanding
GTBP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GTBP Yearly Shares OutstandingGTBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
GTBP Yearly Total Debt VS Total AssetsGTBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

GTBP has an Altman-Z score of -382.31. This is a bad value and indicates that GTBP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -382.31, GTBP is not doing good in the industry: 97.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -382.31
ROIC/WACCN/A
WACCN/A
GTBP Yearly LT Debt VS Equity VS FCFGTBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 0.73 indicates that GTBP may have some problems paying its short term obligations.
GTBP has a Current ratio of 0.73. This is amonst the worse of the industry: GTBP underperforms 89.83% of its industry peers.
GTBP has a Quick Ratio of 0.73. This is a bad value and indicates that GTBP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.73, GTBP is not doing good in the industry: 89.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.73
Quick Ratio 0.73
GTBP Yearly Current Assets VS Current LiabilitesGTBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.19% over the past year.
EPS 1Y (TTM)71.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GTBP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.62%
EPS Next 2Y30.67%
EPS Next 3Y23.35%
EPS Next 5Y12.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GTBP Yearly Revenue VS EstimatesGTBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2029 2030 2031 20B 40B 60B 80B
GTBP Yearly EPS VS EstimatesGTBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GTBP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GTBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GTBP Price Earnings VS Forward Price EarningsGTBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTBP Per share dataGTBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

GTBP's earnings are expected to grow with 23.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.67%
EPS Next 3Y23.35%

More info and screens

0

5. Dividend

5.1 Amount

GTBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GT BIOPHARMA INC

NASDAQ:GTBP (12/9/2025, 8:04:29 PM)

After market: 0.64 0 (0%)

0.64

-0.01 (-1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)02-19 2026-02-19/amc
Inst Owners6.89%
Inst Owner Change96.51%
Ins Owners2.31%
Ins Owner Change0%
Market Cap6.81M
Revenue(TTM)N/A
Net Income(TTM)-11.67M
Analysts82.86
Price Target8.16 (1175%)
Short Float %14.4%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.23%
Min EPS beat(2)-5%
Max EPS beat(2)49.45%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.27%
PT rev (3m)-27.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-26.72%
EPS NY rev (3m)-26.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0
BVpS-0.09
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -439.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.21%
ROA(5y)-233.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.73
Quick Ratio 0.73
Altman-Z -382.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-19.62%
EPS Next 2Y30.67%
EPS Next 3Y23.35%
EPS Next 5Y12.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-98952%
EBIT Next 3Y-913.74%
EBIT Next 5YN/A
FCF growth 1Y15.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.22%
OCF growth 3YN/A
OCF growth 5YN/A

GT BIOPHARMA INC / GTBP FAQ

What is the fundamental rating for GTBP stock?

ChartMill assigns a fundamental rating of 0 / 10 to GTBP.


Can you provide the valuation status for GT BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to GT BIOPHARMA INC (GTBP). This can be considered as Overvalued.


How profitable is GT BIOPHARMA INC (GTBP) stock?

GT BIOPHARMA INC (GTBP) has a profitability rating of 0 / 10.


Can you provide the financial health for GTBP stock?

The financial health rating of GT BIOPHARMA INC (GTBP) is 0 / 10.


Can you provide the expected EPS growth for GTBP stock?

The Earnings per Share (EPS) of GT BIOPHARMA INC (GTBP) is expected to decline by -19.62% in the next year.